Difficulty: Medium
Average Score: 82%
Practice
A client beginning medication therapy with montelukast (Singulair) asks the nurse how the medication is helping the symptoms. Which is the nurse's best response?
Correct answer
A
Rationale
Montelukast (Singulair), a leukotriene modifier, decreases inflammation and mucus secretion (A) by blocking leukotrienes mediators of asthma's bronchoconstriction and mucosal swelling. This reduces airway obstruction, easing symptoms. Increasing mucus (B) worsens blockage; bronchodilation isn't its role beta-agonists do that. It doesn't stop smooth muscle contraction via nerves (C) or shield from allergens (D) it mitigates their effects post-exposure. This anti-inflammatory action, distinct from rescue inhalers, suits maintenance therapy, critical for patient understanding of its preventive role, a nursing priority to ensure adherence and clarify its place in asthma management.